/
LRMR
$4.27-$0.10 (-2.29%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$454.0M
104M shares
52-week range
$2.72 – $6.42
42% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-9.52
Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
www.larimartx.com- Employees
- 71
- IPO / List date
- May 29, 2020
- HQ
- BALA CYNWYD, PA
Held by traders on TradeandTell
No one on the platform currently holds LRMR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 739,942 | $3.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LRMR yet.
